Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2012

01.01.2012 | Topic Review

Novel approaches to treating leptomeningeal metastases

verfasst von: Jai Grewal, Marlon Garzo Saria, Santosh Kesari

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Leptomeningeal metastasis is a devastating complication of the central nervous system in patients with late-stage solid or hematological cancers. Leptomeningeal metastasis results from the multifocal seeding of the leptomeninges by malignant cancer cells. Although central nervous system metastasis usually presents in patients with widely disseminated and progressive late-stage cancer, malignant cells may spread to the cerebrospinal fluid during earlier disease stages in particularly aggressive cancers. Treatment of leptomeningeal metastasis is largely palliative but will often provide stabilization and protection from further neurological deterioration and improve quality of life. There is a need to raise awareness of the impact of leptomeningeal metastases on cancer patients and its known and putative biological basis. Novel diagnostic approaches include identification of biomarkers that may stratify the risk for developing leptomeningeal metastasis. Current therapies can be used more effectively while waiting for advanced treatments to be developed.
Literatur
1.
Zurück zum Zitat Kesari S, Batchelor TT (2003) Leptomeningeal metastases. Neurol Clin N Am 21:25–66 Kesari S, Batchelor TT (2003) Leptomeningeal metastases. Neurol Clin N Am 21:25–66
3.
Zurück zum Zitat Groves MD, Hess KR, Puduvalli VK et al (2009) Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 4:229–234CrossRef Groves MD, Hess KR, Puduvalli VK et al (2009) Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 4:229–234CrossRef
4.
Zurück zum Zitat Mitchell MS (1989) Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol 7:1701–1709PubMed Mitchell MS (1989) Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol 7:1701–1709PubMed
5.
Zurück zum Zitat O’Meara WP, Borkar SA, Stambuk HE et al (2007) Leptomeningeal metastasis. Curr Probl Cancer 31:372–424CrossRef O’Meara WP, Borkar SA, Stambuk HE et al (2007) Leptomeningeal metastasis. Curr Probl Cancer 31:372–424CrossRef
7.
Zurück zum Zitat Yap HY, Yap BS, Rasmussen S et al (1982) Treatment for meningeal carcinomatosis in breast cancer. Cancer 50:219–222PubMedCrossRef Yap HY, Yap BS, Rasmussen S et al (1982) Treatment for meningeal carcinomatosis in breast cancer. Cancer 50:219–222PubMedCrossRef
8.
Zurück zum Zitat Jorda M, Ganjei-Azar P, Nadji M (1998) Cytologic characteristics of meningeal carcinomatosis. Increased diagnostic accuracy using carcinoembryonic antigen and epithelial membrane antigen immunocytochemistry. Arch Neurol 55:181–184PubMedCrossRef Jorda M, Ganjei-Azar P, Nadji M (1998) Cytologic characteristics of meningeal carcinomatosis. Increased diagnostic accuracy using carcinoembryonic antigen and epithelial membrane antigen immunocytochemistry. Arch Neurol 55:181–184PubMedCrossRef
9.
Zurück zum Zitat Chamberlain MC (2006) CSF Disseminated primary brain tumors. In: Newton HB (ed) Handbook of brain tumor chemotherapy. Elsevier Science, San Diego, pp 316–326CrossRef Chamberlain MC (2006) CSF Disseminated primary brain tumors. In: Newton HB (ed) Handbook of brain tumor chemotherapy. Elsevier Science, San Diego, pp 316–326CrossRef
10.
Zurück zum Zitat Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75:5–14PubMedCrossRef Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75:5–14PubMedCrossRef
11.
Zurück zum Zitat Glass JP, Melamed M, Chernik NL et al (1979) Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29:1369–1375PubMed Glass JP, Melamed M, Chernik NL et al (1979) Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29:1369–1375PubMed
12.
Zurück zum Zitat Gleissner B, Chamberlain MC (2007) Treatment of CNS dissemination in systemic lymphoma. J Neurooncol 84:107–117PubMedCrossRef Gleissner B, Chamberlain MC (2007) Treatment of CNS dissemination in systemic lymphoma. J Neurooncol 84:107–117PubMedCrossRef
13.
Zurück zum Zitat Hatton C (2005) Lymphomatous meningitis. Haematologica Rep 1:108–109 Hatton C (2005) Lymphomatous meningitis. Haematologica Rep 1:108–109
14.
15.
Zurück zum Zitat Yoshida S, Morii K, Watanabe M et al (2000) Characteristic features of malignant lymphoma with central nervous system involvement. Surg Neurol 53:163–167PubMedCrossRef Yoshida S, Morii K, Watanabe M et al (2000) Characteristic features of malignant lymphoma with central nervous system involvement. Surg Neurol 53:163–167PubMedCrossRef
16.
Zurück zum Zitat Glantz MJ, Cole BF, Glantz LK et al (1998) Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 82:733–739PubMedCrossRef Glantz MJ, Cole BF, Glantz LK et al (1998) Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 82:733–739PubMedCrossRef
17.
Zurück zum Zitat Ward MS (1999) The use of flow cytometry in the diagnosis and monitoring of malignant hematological disorders. Pathology 31:382–392PubMedCrossRef Ward MS (1999) The use of flow cytometry in the diagnosis and monitoring of malignant hematological disorders. Pathology 31:382–392PubMedCrossRef
18.
Zurück zum Zitat Johanson CE, Duncan JA, Stopa EG et al (2005) Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route. Pharm Res 22:1011–1037PubMedCrossRef Johanson CE, Duncan JA, Stopa EG et al (2005) Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route. Pharm Res 22:1011–1037PubMedCrossRef
19.
Zurück zum Zitat Kobayashi Z, Tsuchiya K, Machida A et al (2009) Metastatic CNS lymphoma presenting with periventricular dissemination–MRI and neuropathological finding in an autopsy case. J Neurological Sci 277:109–113CrossRef Kobayashi Z, Tsuchiya K, Machida A et al (2009) Metastatic CNS lymphoma presenting with periventricular dissemination–MRI and neuropathological finding in an autopsy case. J Neurological Sci 277:109–113CrossRef
20.
Zurück zum Zitat Levine S (1987) Choroid plexus: target for systemic disease and pathway to the brain. Lab Invest 56:231–233PubMed Levine S (1987) Choroid plexus: target for systemic disease and pathway to the brain. Lab Invest 56:231–233PubMed
21.
Zurück zum Zitat Oldstone MB, Southern PJ (1993) Trafficking of activated cytotoxic T lymphocytes into the central nervous system: use of a transgenic model. J Neuroimmunol 46:25–31PubMedCrossRef Oldstone MB, Southern PJ (1993) Trafficking of activated cytotoxic T lymphocytes into the central nervous system: use of a transgenic model. J Neuroimmunol 46:25–31PubMedCrossRef
22.
23.
Zurück zum Zitat Alix-Panabieres C, Riethdorf S, Pantel K (2008) Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res 14:5013–5021PubMedCrossRef Alix-Panabieres C, Riethdorf S, Pantel K (2008) Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res 14:5013–5021PubMedCrossRef
24.
Zurück zum Zitat Kakarala M, Wicha MS (2008) Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 26:2813–2820PubMedCrossRef Kakarala M, Wicha MS (2008) Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 26:2813–2820PubMedCrossRef
25.
Zurück zum Zitat Li X, Lewis MT, Huang J et al (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672–679PubMedCrossRef Li X, Lewis MT, Huang J et al (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672–679PubMedCrossRef
26.
Zurück zum Zitat Fidler IJ, Langley RR, Kerbel RS et al (2005) Angiogenesis. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice in oncology. Lippincott Williams & Wilkins, New York, pp 129–135 Fidler IJ, Langley RR, Kerbel RS et al (2005) Angiogenesis. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice in oncology. Lippincott Williams & Wilkins, New York, pp 129–135
27.
Zurück zum Zitat Kraft A, Weindel K, Ochs A et al (1999) Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85:178–187PubMedCrossRef Kraft A, Weindel K, Ochs A et al (1999) Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85:178–187PubMedCrossRef
28.
Zurück zum Zitat Stockhammer G, Poewe W, Burgstaller S et al (2000) Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 54:1670–1676PubMed Stockhammer G, Poewe W, Burgstaller S et al (2000) Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 54:1670–1676PubMed
29.
Zurück zum Zitat Goswami S, Phillippar U, Sun D et al (2009) Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo. Clin Exp Metastasis 26:153–159PubMedCrossRef Goswami S, Phillippar U, Sun D et al (2009) Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo. Clin Exp Metastasis 26:153–159PubMedCrossRef
30.
Zurück zum Zitat Kadoch C, Treseler P, Rubenstein JL (2006) Molecular pathogenesis of primary central nervous system lymphoma. Neurosurg Focus 21:E1PubMedCrossRef Kadoch C, Treseler P, Rubenstein JL (2006) Molecular pathogenesis of primary central nervous system lymphoma. Neurosurg Focus 21:E1PubMedCrossRef
31.
Zurück zum Zitat Lee B-C, Lee T-H, Avraham S et al (2004) Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1α in breast cancer cell migration through human brain microvascular endothelial cells. Mol Cancer Res 2:327–338PubMed Lee B-C, Lee T-H, Avraham S et al (2004) Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1α in breast cancer cell migration through human brain microvascular endothelial cells. Mol Cancer Res 2:327–338PubMed
32.
Zurück zum Zitat Singh S, Nannuru KC, Sandanandam A et al (2009) CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer 100:1638–1646PubMedCrossRef Singh S, Nannuru KC, Sandanandam A et al (2009) CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer 100:1638–1646PubMedCrossRef
33.
Zurück zum Zitat Philippar U, Roussos ET, Oser M et al (2008) A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev Cell 15:813–828PubMedCrossRef Philippar U, Roussos ET, Oser M et al (2008) A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev Cell 15:813–828PubMedCrossRef
34.
Zurück zum Zitat Wyckoff J, Wang W, Lin EY et al (2004) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64:7022–7029PubMedCrossRef Wyckoff J, Wang W, Lin EY et al (2004) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64:7022–7029PubMedCrossRef
35.
Zurück zum Zitat Van Oostenbrugge RJ, Hopman AHN, Ramaekers FCS et al (1998) In situ hybridization: a possible diagnostic aid in leptomeningeal metastasis. J Neurooncol 38:127–133PubMedCrossRef Van Oostenbrugge RJ, Hopman AHN, Ramaekers FCS et al (1998) In situ hybridization: a possible diagnostic aid in leptomeningeal metastasis. J Neurooncol 38:127–133PubMedCrossRef
36.
Zurück zum Zitat Van Oostenbrugge RJ, Hopman AHN, Arends JW et al (2000) Treatment of leptomeningeal metastasis evaluated by interphase cytogenetics. J Clin Oncol 18:2053–2058PubMed Van Oostenbrugge RJ, Hopman AHN, Arends JW et al (2000) Treatment of leptomeningeal metastasis evaluated by interphase cytogenetics. J Clin Oncol 18:2053–2058PubMed
37.
Zurück zum Zitat Baehring JM, Hochberg FH, Betensky RA et al (2006) Immunoglobulin gene rearrangement analysis in cerebrospinal fluid of patients with lymphoproliferative processes. J Neurol Sci 247:208–216PubMedCrossRef Baehring JM, Hochberg FH, Betensky RA et al (2006) Immunoglobulin gene rearrangement analysis in cerebrospinal fluid of patients with lymphoproliferative processes. J Neurol Sci 247:208–216PubMedCrossRef
38.
Zurück zum Zitat Gleissner B, Siehl J, Korfel A et al (2002) CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 58:390–396PubMed Gleissner B, Siehl J, Korfel A et al (2002) CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 58:390–396PubMed
39.
Zurück zum Zitat Berg SL, Chamberlain MC (2003) Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Curr Oncol Rep 5:29–40PubMedCrossRef Berg SL, Chamberlain MC (2003) Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Curr Oncol Rep 5:29–40PubMedCrossRef
40.
Zurück zum Zitat Berg SL, Chamberlain MC (2005) Current treatment of leptomeningeal metastases: systemic chemotherapy, intrathecal chemotherapy and symptom management. Cancer Treat Res 125:121–146PubMedCrossRef Berg SL, Chamberlain MC (2005) Current treatment of leptomeningeal metastases: systemic chemotherapy, intrathecal chemotherapy and symptom management. Cancer Treat Res 125:121–146PubMedCrossRef
41.
Zurück zum Zitat Chamberlain MC, Nolan C, Abrey LE (2005) Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. J Neurooncol 75:71–83PubMedCrossRef Chamberlain MC, Nolan C, Abrey LE (2005) Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. J Neurooncol 75:71–83PubMedCrossRef
42.
Zurück zum Zitat Chamberlain MC, Kormanik PA, Barba D (1997) Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 87:694–699PubMedCrossRef Chamberlain MC, Kormanik PA, Barba D (1997) Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 87:694–699PubMedCrossRef
43.
Zurück zum Zitat Siegal T, Lossos A, Pfeffer MR (1994) Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 44:1463–1469PubMed Siegal T, Lossos A, Pfeffer MR (1994) Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 44:1463–1469PubMed
44.
Zurück zum Zitat Glantz MJ, Hall WA, Cole BF et al (1995) Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 75:2919–2931PubMedCrossRef Glantz MJ, Hall WA, Cole BF et al (1995) Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 75:2919–2931PubMedCrossRef
45.
Zurück zum Zitat Glantz MJ, Hall WA, Cole BF et al (1995) Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 75(12):2919–2931PubMedCrossRef Glantz MJ, Hall WA, Cole BF et al (1995) Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 75(12):2919–2931PubMedCrossRef
46.
Zurück zum Zitat Chamberlain MC, Glantz M (2006) Ventriculoperitoneal shunt in patients with leptomeningeal metastases. Neurology 66:783PubMedCrossRef Chamberlain MC, Glantz M (2006) Ventriculoperitoneal shunt in patients with leptomeningeal metastases. Neurology 66:783PubMedCrossRef
47.
Zurück zum Zitat Omuro AM, Lallana EC, Bilsky MH et al (2005) Ventriculoperitoneal shunt in patients with leptomeningeal metastases. Neurology 10:1625–1627CrossRef Omuro AM, Lallana EC, Bilsky MH et al (2005) Ventriculoperitoneal shunt in patients with leptomeningeal metastases. Neurology 10:1625–1627CrossRef
48.
Zurück zum Zitat Mocco J, Tomey MI, Komotar RJ et al (2006) Ventriculoperitoneal shunting of idiopathic normal pressure hydrocephalus increases midbrain size: a potential mechanism for gait improvement. Neurosurgery 59:847–851PubMedCrossRef Mocco J, Tomey MI, Komotar RJ et al (2006) Ventriculoperitoneal shunting of idiopathic normal pressure hydrocephalus increases midbrain size: a potential mechanism for gait improvement. Neurosurgery 59:847–851PubMedCrossRef
49.
Zurück zum Zitat Schiff D, Kline C, Meltzer H et al (2009) Palliative venticuloperitoneal shunt in a pediatric patient with recurrent metastatic medulloblastoma. J Palliat Med 12:391–393PubMedCrossRef Schiff D, Kline C, Meltzer H et al (2009) Palliative venticuloperitoneal shunt in a pediatric patient with recurrent metastatic medulloblastoma. J Palliat Med 12:391–393PubMedCrossRef
50.
Zurück zum Zitat Lokich J, Levine H, Nasser I (1998) Malignancy-related hydrocephalus: clinical features and results of ventricular peritoneal shunt procedure in three patients. Am J Clin Oncol 21:366–368PubMedCrossRef Lokich J, Levine H, Nasser I (1998) Malignancy-related hydrocephalus: clinical features and results of ventricular peritoneal shunt procedure in three patients. Am J Clin Oncol 21:366–368PubMedCrossRef
51.
Zurück zum Zitat Eralp Y, Saip P, Aydin Z et al (2008) Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt. Gynecol Oncol 108:248–250PubMedCrossRef Eralp Y, Saip P, Aydin Z et al (2008) Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt. Gynecol Oncol 108:248–250PubMedCrossRef
52.
Zurück zum Zitat Matsumae M, Sato O, Itoh K et al (1989) Quantification of cerebrospinal fluid shunt flow rates. Assessment of the programmable pressure valve. Childs Nerv Syst 5:356–360PubMedCrossRef Matsumae M, Sato O, Itoh K et al (1989) Quantification of cerebrospinal fluid shunt flow rates. Assessment of the programmable pressure valve. Childs Nerv Syst 5:356–360PubMedCrossRef
53.
Zurück zum Zitat Chiafery M (2006) Care and management of the child with shunted hydrocephalus. Pediatr Nurs 32:222–225PubMed Chiafery M (2006) Care and management of the child with shunted hydrocephalus. Pediatr Nurs 32:222–225PubMed
54.
Zurück zum Zitat Glantz MJ, LaFollette S, Jaeckle KA et al (1999) Randomized trial of a slow-release versus standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110–3116PubMed Glantz MJ, LaFollette S, Jaeckle KA et al (1999) Randomized trial of a slow-release versus standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110–3116PubMed
55.
Zurück zum Zitat Garcia-Marco JA, Panizo C, Garcia ES et al (2009) Efficacy and safely of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer 115:1892–1898PubMedCrossRef Garcia-Marco JA, Panizo C, Garcia ES et al (2009) Efficacy and safely of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer 115:1892–1898PubMedCrossRef
56.
Zurück zum Zitat Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147–1157PubMedCrossRef Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147–1157PubMedCrossRef
57.
Zurück zum Zitat Cameron DA, Stein S (2008) Drug insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol 5:512–520PubMedCrossRef Cameron DA, Stein S (2008) Drug insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol 5:512–520PubMedCrossRef
58.
Zurück zum Zitat Lin NU, Diéras V, Paul D et al (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452–1459PubMedCrossRef Lin NU, Diéras V, Paul D et al (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452–1459PubMedCrossRef
59.
Zurück zum Zitat Onishi H, Morisaki T, Nakafusa Y et al. (2011) Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer. Int J Clin Oncol. doi:10.1007/s10147-011-0195-5 Onishi H, Morisaki T, Nakafusa Y et al. (2011) Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer. Int J Clin Oncol. doi:10.​1007/​s10147-011-0195-5
60.
Zurück zum Zitat Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139PubMedCrossRef Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139PubMedCrossRef
61.
Zurück zum Zitat Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedCrossRef Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedCrossRef
62.
Zurück zum Zitat Inoue A, Kobayashi K, Usui K et al (2009) First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27:1394–1400PubMedCrossRef Inoue A, Kobayashi K, Usui K et al (2009) First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27:1394–1400PubMedCrossRef
63.
Zurück zum Zitat Omuro AM, Kris MG, Miller VA et al (2005) High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 103:2344–2348PubMedCrossRef Omuro AM, Kris MG, Miller VA et al (2005) High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 103:2344–2348PubMedCrossRef
64.
Zurück zum Zitat Jackman DM, Kesari S, Cioffredi L et al. (2009) Phase I study of high dose gefitinib in patients with leptomeningeal metastases from EGFR-mutant non-small cell lung cancer. Presented at the 13th World Congress on Lung Cancer San Francisco, 31st July–4th August 2009; Poster P1.189 Jackman DM, Kesari S, Cioffredi L et al. (2009) Phase I study of high dose gefitinib in patients with leptomeningeal metastases from EGFR-mutant non-small cell lung cancer. Presented at the 13th World Congress on Lung Cancer San Francisco, 31st July–4th August 2009; Poster P1.189
65.
Zurück zum Zitat Yi HG, Kim HJ, Kim YJ et al (2009) Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 65:80–84PubMedCrossRef Yi HG, Kim HJ, Kim YJ et al (2009) Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 65:80–84PubMedCrossRef
66.
Zurück zum Zitat Jackman DM, Holmes A, Lindeman N et al (2006) Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 24:4517–4520PubMedCrossRef Jackman DM, Holmes A, Lindeman N et al (2006) Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 24:4517–4520PubMedCrossRef
67.
Zurück zum Zitat Clarke JL, Pao W, Wu N et al (2010) High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99(2):283–286PubMedCrossRef Clarke JL, Pao W, Wu N et al (2010) High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99(2):283–286PubMedCrossRef
68.
Zurück zum Zitat Tetsumoto S, Osa A, Kijima T et al (2011) Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib. Int J Clin Oncol. doi:10.1007/s10147-011-0256-9 Tetsumoto S, Osa A, Kijima T et al (2011) Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib. Int J Clin Oncol. doi:10.​1007/​s10147-011-0256-9
69.
Zurück zum Zitat Shigekawa T, Takeuchi H, Misumi M et al (2009) Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report. Breast Cancer 16:88–92PubMedCrossRef Shigekawa T, Takeuchi H, Misumi M et al (2009) Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report. Breast Cancer 16:88–92PubMedCrossRef
70.
Zurück zum Zitat Ekenel M, Hormigo AM, Peak S et al (2007) Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 85:223–227PubMedCrossRef Ekenel M, Hormigo AM, Peak S et al (2007) Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 85:223–227PubMedCrossRef
71.
Zurück zum Zitat Tham YL, Hinckley L, Teh BS et al (2006) Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer 7:164–166PubMedCrossRef Tham YL, Hinckley L, Teh BS et al (2006) Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer 7:164–166PubMedCrossRef
72.
Zurück zum Zitat Paydas S, Bicakci K, Yavuz S (2009) Dramatic response with capecitabine after cranial radiation to the brain parenchymal and leptomeningeal metastases from lung cancer. Eur J Intern Med 20:96–99PubMedCrossRef Paydas S, Bicakci K, Yavuz S (2009) Dramatic response with capecitabine after cranial radiation to the brain parenchymal and leptomeningeal metastases from lung cancer. Eur J Intern Med 20:96–99PubMedCrossRef
73.
Zurück zum Zitat Rivera E, Meyers C, Groves M et al (2006) Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 107:1348–1354PubMedCrossRef Rivera E, Meyers C, Groves M et al (2006) Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 107:1348–1354PubMedCrossRef
74.
Zurück zum Zitat Fidler IJ, Yano S, Zhang RD et al (2002) The seed and soil hypothesis: vascularization and brain metastases. Lancet Oncol 3:53–57PubMedCrossRef Fidler IJ, Yano S, Zhang RD et al (2002) The seed and soil hypothesis: vascularization and brain metastases. Lancet Oncol 3:53–57PubMedCrossRef
75.
Zurück zum Zitat Bhaskara A, Eng C (2008) Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases. Clin Colorectal Cancer 7:65–68PubMedCrossRef Bhaskara A, Eng C (2008) Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases. Clin Colorectal Cancer 7:65–68PubMedCrossRef
76.
Zurück zum Zitat Kim LS, Huang S, Lu W et al (2004) Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis 21:107–118PubMedCrossRef Kim LS, Huang S, Lu W et al (2004) Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis 21:107–118PubMedCrossRef
77.
78.
Zurück zum Zitat Ku GY, Krol G, Ilson DH (2007) Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan. J Clin Oncol 25:e14–e16PubMedCrossRef Ku GY, Krol G, Ilson DH (2007) Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan. J Clin Oncol 25:e14–e16PubMedCrossRef
79.
Zurück zum Zitat Cvetkovic RS, Perry CM (2006) Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Drugs 66:791–820PubMedCrossRef Cvetkovic RS, Perry CM (2006) Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Drugs 66:791–820PubMedCrossRef
80.
Zurück zum Zitat Marcus R, Hagenbeek A (2007) The therapeutic use of rituximab in non-Hodgkin’s lymphoma. Eur J Haematol Suppl 67:5–14PubMedCrossRef Marcus R, Hagenbeek A (2007) The therapeutic use of rituximab in non-Hodgkin’s lymphoma. Eur J Haematol Suppl 67:5–14PubMedCrossRef
81.
Zurück zum Zitat Rubenstein JL, Fridlyand J, Abrey L et al (2007) Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 25:1350–1355PubMedCrossRef Rubenstein JL, Fridlyand J, Abrey L et al (2007) Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 25:1350–1355PubMedCrossRef
82.
Zurück zum Zitat Chamberlain MC, Johnston SK, Van Horn A et al (2009) Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol 91:271–277PubMedCrossRef Chamberlain MC, Johnston SK, Van Horn A et al (2009) Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol 91:271–277PubMedCrossRef
83.
Zurück zum Zitat Bernstein SH, Unger JM, Leblanc M et al (2009) Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma: a 20-year follow-up analysis of SWOG 8516—the southwest oncology group. J Clin Oncol 27:114–119PubMedCrossRef Bernstein SH, Unger JM, Leblanc M et al (2009) Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma: a 20-year follow-up analysis of SWOG 8516—the southwest oncology group. J Clin Oncol 27:114–119PubMedCrossRef
84.
Zurück zum Zitat Canales M, Peñarrubia MJ, Salar A et al. (2008) Efficacy and safety of intrathecal liposomal cytarabine injection given prophylactically in patients with high-risk diffuse large B-cell lymphoma: a report of 24 patients in Spain. Abstract Presented at: the 13th Congress of the European Hematology Association, Copenhagen, Denmark, 12–15 June Canales M, Peñarrubia MJ, Salar A et al. (2008) Efficacy and safety of intrathecal liposomal cytarabine injection given prophylactically in patients with high-risk diffuse large B-cell lymphoma: a report of 24 patients in Spain. Abstract Presented at: the 13th Congress of the European Hematology Association, Copenhagen, Denmark, 12–15 June
85.
Zurück zum Zitat Lim HY, Thiel E, Glantz MJ (2008) To protect and defend: central nervous system prophylaxis in patients with non-Hodkin’s lymphoma. Curr Opin Oncol 20:495–501PubMedCrossRef Lim HY, Thiel E, Glantz MJ (2008) To protect and defend: central nervous system prophylaxis in patients with non-Hodkin’s lymphoma. Curr Opin Oncol 20:495–501PubMedCrossRef
Metadaten
Titel
Novel approaches to treating leptomeningeal metastases
verfasst von
Jai Grewal
Marlon Garzo Saria
Santosh Kesari
Publikationsdatum
01.01.2012
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2012
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-011-0686-2

Weitere Artikel der Ausgabe 2/2012

Journal of Neuro-Oncology 2/2012 Zur Ausgabe

Clinical Study–Patient Study

Oligodendrogliomas in children

Laboratory Investigation - Human/Animal Tissue

Expression profile of frizzled receptors in human medulloblastomas

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.